Myriad Wins Gene Patent Ruling From U.S. Appeals Court

August 16, 2012 | A federal appeals court has revived its decision to uphold Myriad Genetics' patents on two genes linked to breast and ovarian cancer, after the U.S. Supreme Court told it to take another look at the hotly contested case. A 2-1 panel of the U.S. Federal Circuit Court of Appeals in Washington, D.C. upheld the biotechnology company's right to patent 'isolated' DNA molecules or genes, known as BRCA1 and BRCA2, while denying its effort to patent methods directed to comparing or analyzing DNA sequences. Reuters